GO
Loading...

Merck & Co Inc

More

  • Stocks rise; another record finish for S&P 500 Thursday, 29 May 2014 | 4:57 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks rose Thursday after the economy contracting in the first quarter but jobless claims falling more than hoped.

  • LONDON, May 29- GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter. Private equity firms approached by GSK include Advent International, Blackstone and KKR, the sources said, and the drugmaker is being advised by Lazard.

  • Immuno-what? How these cancer therapies work Thursday, 29 May 2014 | 12:27 PM ET
    Laboratory which develops therapeutic vaccinations to treat cancer.

    A key theme at this year's ASCO meeting will be immunotherapies. How do these treatments work?

  • How AstraZeneca escaped Pfizer clutches...this time Tuesday, 27 May 2014 | 8:20 AM ET

    Could things have turned out differently? Yes, according to one source in the AstraZeneca camp who pointed to a flaw in Pfizer's strategy.

  • AstraZeneca free for now as May 26 deadline passes. LONDON, May 27- On a sunny day in San Francisco last January, AstraZeneca Chief Executive Pascal Soriot was on his way to the Westin St. Francis hotel on Union Square to give investors some unexpectedly good news.

  • Stocks end higher for second day; S&P 500 near record Thursday, 22 May 2014 | 4:27 PM ET

    Stocks rose modestly on Thursday, extending the prior day's rally.

  • Why there's no end in sight for higher drug costs Thursday, 22 May 2014 | 7:06 AM ET
    About 40 protesters from across the country converged on Gilead Sciences headquarters in Foster City, Calif., Nov. 14, 2012, calling on the drug maker to lower prices for its Stribild AIDS medication.

    The mounting scrutiny of prescription drug prices in the U.S. reached fever pitch with total spending last year rising 3.2 percent, to $329.2 billion.

  • The latest salvo in the war on escalating U.S. healthcare costs came from AHIP- America's Health Insurance Plans- and targeted Sovaldi, the new $84,000 hepatitis C treatment from Gilead Sciences Inc..

  • May 20- The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels.

  • Drug flops from 2004 haunt AstraZeneca investors Tuesday, 20 May 2014 | 9:37 AM ET

    *AstraZeneca has had more than fair share of flops in past. LONDON, May 20- AstraZeneca's confidence in its promising new drugs may have seen off Pfizer's $118 billion takeover bid for now, but investors are left contemplating the lessons from 2004, when it was also trumpeting its product pipeline.

  • SHANGHAI, May 18- Chinese corruption charges against executives of British drugmaker GlaxoSmithKline Plc could be just the start of the pharmaceutical industry's problems in its biggest emerging drugs market, according to industry sources in China.

  • May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.

  • May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.

  • This year, at ASCO, all eyes are on pharma Wednesday, 14 May 2014 | 3:41 PM ET

    Some stocks moved after the bell after abstracts for the American Society of Clinical Oncology meeting dropped Wednesday.

  • Europe shares close mixed; ECB policy eyed Wednesday, 14 May 2014 | 11:49 AM ET

    European shares closed mixed on Wednesday, after wavering throughout the day, with investors eyeing European Central Bank policy.

  • Another 'disturbing' trend among US companies Monday, 12 May 2014 | 11:15 AM ET
    A research scientist for IBM Research works in the lab at the IBM Research - Almaden facility in San Jose, Calif., Oct. 28, 2011.

    U.S. companies in industries such as tech and medicine depend on cutting edge research and development to make money. So why are they cutting back?

  • May 12- Tesaro Inc said its drug for the prevention of chemotherapy-induced nausea and vomiting met the main goal in a third late-stage trial. Tesaro shares jumped nearly 15 percent to $27.51 in premarket trading, after the company said the drug, rolapitant, achieved statistical significance over standard therapy in 532 cancer patients.

  • Which M&A deal is best for shareholders? Monday, 12 May 2014 | 12:44 AM ET

    Which M&A deal represents the best value for shareholders?

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks rose on Friday, with consumer discretionary leading late session gains.

  • Hepatitis C drug costs beat alternative: Merck Wednesday, 7 May 2014 | 4:01 PM ET
    Ken Frazier, president and CEO of Merck.

    May the best drug win. That's how Merck Chief Executive Ken Frazier views the rising competition for hepatitis C treatments.